Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W
J Hematol Oncol. 2024; 17(1):105.
PMID: 39501358
PMC: 11539560.
DOI: 10.1186/s13045-024-01625-7.
Chen M, Zhang F, Goedegebuure S, Gillanders W
Front Immunol. 2024; 15:1393451.
PMID: 38903502
PMC: 11188312.
DOI: 10.3389/fimmu.2024.1393451.
Beckmann K, Reitinger C, Yan X, Carle A, Blumle E, Jurkschat N
Antibodies (Basel). 2024; 13(2).
PMID: 38651411
PMC: 11036229.
DOI: 10.3390/antib13020031.
Liu Y, Huang Y, Cui H, Wang Y, Ma Z, Xiang Y
Cancer Cell Int. 2024; 24(1):100.
PMID: 38461238
PMC: 10924995.
DOI: 10.1186/s12935-024-03290-9.
Lim S, Beers S, Al-Shamkhani A, Cragg M
Clin Cancer Res. 2023; 30(9):1712-1723.
PMID: 38153346
PMC: 7615925.
DOI: 10.1158/1078-0432.CCR-23-1014.
Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y, Xu Y, Liu C, Yuan C, Zhang Y
Front Immunol. 2023; 14:1233260.
PMID: 37799714
PMC: 10548142.
DOI: 10.3389/fimmu.2023.1233260.
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L, Huang Z, Mei H, Hu Y
Signal Transduct Target Ther. 2023; 8(1):306.
PMID: 37591844
PMC: 10435569.
DOI: 10.1038/s41392-023-01521-5.
Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma.
Lin H, Liu Y, Caroland K, Lin J
Cancers (Basel). 2023; 15(13).
PMID: 37444617
PMC: 10340421.
DOI: 10.3390/cancers15133507.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler A, Smith D, Phillips T, Curti B, Goel S, Mehta A
J Immunother Cancer. 2023; 11(6).
PMID: 37385724
PMC: 10314623.
DOI: 10.1136/jitc-2022-005584.
Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques.
Yan X, Ols S, Cerveira R, Lenart K, Hellgren F, Ye K
Cell Mol Life Sci. 2023; 80(7):189.
PMID: 37353664
PMC: 10289945.
DOI: 10.1007/s00018-023-04828-2.
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Mukherjee D, Romano E, Walshaw R, Zeef L, Banyard A, Kitcatt S
Oncoimmunology. 2023; 12(1):2223094.
PMID: 37332616
PMC: 10274532.
DOI: 10.1080/2162402X.2023.2223094.
Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
Manso T, Kushwaha A, Abdollahi N, Duroux P, Giudicelli V, Kossida S
Front Immunol. 2023; 14:1129323.
PMID: 37215135
PMC: 10196129.
DOI: 10.3389/fimmu.2023.1129323.
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Pieper A, Spiegelman D, Felder M, Feils A, Tsarovsky N, Zaborek J
Cancer Immunol Immunother. 2023; 72(7):2459-2471.
PMID: 37016127
PMC: 10264285.
DOI: 10.1007/s00262-023-03433-3.
Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
Zhai X, Mao L, Wu M, Liu J, Yu S
Cancers (Basel). 2023; 15(5).
PMID: 36900151
PMC: 10000068.
DOI: 10.3390/cancers15051357.
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker P, Briley A
Sci Transl Med. 2023; 15(682):eabn5649.
PMID: 36753564
PMC: 10440725.
DOI: 10.1126/scitranslmed.abn5649.
Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity.
Pfefferle M, Dubach I, Buzzi R, Durst E, Schulthess-Lutz N, Baselgia L
J Immunother Cancer. 2023; 11(1).
PMID: 36593065
PMC: 9809320.
DOI: 10.1136/jitc-2022-005718.
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
Xiao A, Akilov O
Cells. 2022; 11(22).
PMID: 36429020
PMC: 9688096.
DOI: 10.3390/cells11223591.
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
Behrens L, van den Berg T, van Egmond M
Cancers (Basel). 2022; 14(14).
PMID: 35884427
PMC: 9319280.
DOI: 10.3390/cancers14143366.
Charting roadmaps towards novel and safe synergistic immunotherapy combinations.
Sanmamed M, Berraondo P, Rodriguez-Ruiz M, Melero I
Nat Cancer. 2022; 3(6):665-680.
PMID: 35764745
DOI: 10.1038/s43018-022-00401-1.
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A, Adams 3rd H, Gieseke F, Altintas I, Schoedel K, Blum J
J Immunother Cancer. 2022; 10(6).
PMID: 35688554
PMC: 9189854.
DOI: 10.1136/jitc-2021-004322.